Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (60)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Giangrande, A.
Right arrow Articles by Allaria, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giangrande, A.
Right arrow Articles by Allaria, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1992) 7: 412-421
© 1992 European Renal Association-European Dialysis and Transplant Association

research-article

Ultrasound-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism

A. Giangrande, MD1,, A. Castiglioni, MD1, L. Solbiati, MD2 and P. Allaria, MD1

1Unità Operativa di Nefrologia e Dialisi Busto Arsizio, Italy 2Servizio di Radiologia I, Ospedale Generale Provinciale Busto Arsizio, Italy

Correspondence and offprint requests to: Alberto Giangrande MD, U.O. di Nefrologia e Dialisi, Ospedale Generale Provinciale, Piazza Solaro N. 3, 21052 Busto Arsizio, Italy

To reduce parathyroid hormone concentrations in uraemic patients refractory or hyporesponsive to calcium supplements and active metabolites of vitamin D, we developed in 1982 a new parathyroid ablative technique consisting of percutaneous fineneedle ethanol injection (PFNEI) into enlarged parathyroid glands under ultrasonic guidance. Fifty uraemic patients have been treated. Decreases in carboxy terminal parathyroid hormone (PTH) were 50% or more in 13 of 50 patients followed up (26%) at 1 month, in 13 of 48 (27%) at 6 months, and in 9 of 25 (36%) at 12 months. Decreases of 30% or more in PTH were obtained in 21 of 50 (42%), in 25 of 48 (52%), and in 15 of 25 (60%). In ‘responsive‘ patients, serum total alkaline phosphatase was significantly reduced [from 579 ± 645 U/l to 360 ±354 U/l (P < 0.01) at 6 months, and to 273 ± 311 U/l (P < 0.01) at 12 months] and bone isoenzyme decreased similarly [from 482 ±608 U/l to 256 ±344 U/l (P< 0.005), and to 225±354 U/l (P<0.01)]. The best results were in seven patients who had relapsed after subtotal parathyroidectomy. Declines in PTH of 30% or more were observed in four of seven patients at 1 month, in six of the seven (85%) at 6 months, and in all four patients seen after 12 months. The treatment corrected hypercalcaemia, making it possible to start or to increase daily vitamin D treatment. Side-effects were mild, rare, and transient.

Keywords: uraemia; secondary hyperparathyroidism; parathyroid glands; ethanol injection; sonographic guidance


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NDT PlusHome page
F. Koiwa, T. Hasegawa, R. Tanaka, and T. Kakuta
Indication and efficacy of PEIT in the management of secondary hyperparathyroidism
NDT Plus, August 1, 2008; 1(suppl_3): iii14 - iii17.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Koiwa, T. Kakuta, R. Tanaka, and S. Yumita
Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 522 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. Edevanilson de Barros Gueiros, M. C. Chammas, R. Gerhard, C. F. Dente da Silva Dias Boilesen, I. R. Souza de Oliveira, R. M. Affonso Moyses, and V. Jorgetti
Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism
Nephrol. Dial. Transplant., March 1, 2004; 19(3): 657 - 663.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Fukagawa, M. Kitaoka, Y. Tominaga, T. Akizawa, T. Kakuta, N. Onoda, F. Koiwa, S. Yumita, and K. Kurokawa
Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients
Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii31 - 33.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Nakanishi, S. Yano, R. Nomura, T. Tsukamoto, Y. Shimizu, J. Shin, and M. Fukagawa
Efficacy of direct injection of calcitriol into the parathyroid glands in uraemic patients with moderate to severe secondary hyperparathyroidism
Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii47 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Tanaka, T. Kakuta, T. Fujisaki, S. Tanaka, H. Sakai, K. Kurokawa, and A. Saito
Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography
Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii58 - 61.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Locatelli, J. B. Cannata-Andia, T. B. Drueke, W. H. Horl, D. Fouque, O. Heimburger, and E. Ritz
Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia
Nephrol. Dial. Transplant., May 1, 2002; 17(5): 723 - 731.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.